研究者業績

黒川 友哉

KUROKAWA TOMOYA

基本情報

所属
千葉大学 医学部附属病院臨床試験部 助教
(独)医薬品医療機器総合機構 医療機器審査第一部 専門委員
学位
博士(2020年3月 千葉大学)

研究者番号
80837120
J-GLOBAL ID
201801016551933816
researchmap会員ID
B000309709

学歴

 2

論文

 19
  • Noriyuki Okonogi, Kazutoshi Murata, Shigeru Yamada, Yuji Habu, Makoto Hori, Tomoya Kurokawa, Yosuke Inaba, Tadami Fujiwara, Yasuhisa Fujii, Michiko Hanawa, Yohei Kawasaki, Yoko Hattori, Kazuko Suzuki, Kyoko Tsuyuki, Masaru Wakatsuki, Masashi Koto, Sumitaka Hasegawa, Hitoshi Ishikawa, Hideki Hanaoka, Makio Shozu, Hiroshi Tsuji, Hirokazu Usui
    International journal of molecular sciences 24(13) 2023年6月23日  査読有り
    We conducted a phase Ib study to examine the safety of a combination of carbon-ion RT (CIRT) with durvalumab (MEDI4736; AstraZeneca) in patients with locally advanced cervical cancer. This was an open-label, single-arm study with a modified 3 + 3 design. Patients with newly diagnosed histologically proven locally advanced cervical cancer were enrolled. All patients received 74.4 Gy of CIRT in 20 fractions and concurrent weekly cisplatin (chemo-CIRT) at a dose of 40 mg/m2. Durvalumab was administered (1500 mg/body) at weeks two and six. The primary endpoint was the incidence of adverse events (AEs) and serious AEs (SAEs), including dose-limiting toxicity (DLT). All three enrolled patients completed the treatment without interruption. One patient developed hypothyroidism after treatment and was determined to be an SAE. No other SAEs were observed. The patient recovered after levothyroxine sodium hydrate treatment. None of the AEs, including hypothyroidism, were associated with DLT in the present study. All three patients achieved complete responses within the CIRT region concerning treatment efficacy. This phase 1b trial demonstrates the safety of combining chemo-CIRT and durvalumab for locally advanced cervical cancer in the early phase. Further research is required as only three patients were included in this study.
  • Taiga Miyazaki, Naoki Hosogaya, Yuri Fukushige, Sachiko Takemori, Shinpei Morimoto, Hiroshi Yamamoto, Makoto Hori, Yoshihito Ozawa, Yuki Shiko, Yosuke Inaba, Tomoya Kurokawa, Hideki Hanaoka, Shoya Iwanami, Kwangsu Kim, Shingo Iwami, Koichi Watashi, Ken Miyazawa, Takashi Umeyama, Satoshi Yamagoe, Yoshitsugu Miyazaki, Takaji Wakita, Makoto Sumiyoshi, Tatsuro Hirayama, Koichi Izumikawa, Katsunori Yanagihara, Hiroshi Mukae, Hitoshi Kawasuji, Yoshihiro Yamamoto, Norihito Tarumoto, Hiroshi Ishii, Hideaki Ohno, Kazuhiro Yatera, Hiroshi Kakeya, Yoshiko Kichikawa, Yasuyuki Kato, Tetsuya Matsumoto, Makoto Saito, Hiroshi Yotsuyanagi, Shigeru Kohno
    Microbiology Spectrum 11(3) e0431122 2023年5月4日  査読有り
    The anti-HIV drug nelfinavir suppresses the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro . However, its efficacy in patients with COVID-19 has not been studied.
  • Masato Mima, Atsushi Okabe, Takayuki Hoshii, Takuya Nakagawa, Tomoya Kurokawa, Satoru Kondo, Harue Mizokami, Masaki Fukuyo, Ryoji Fujiki, Bahityar Rahmutulla, Tomokazu Yoshizaki, Toyoyuki Hanazawa, Kiyoshi Misawa, Atsushi Kaneda
    International journal of cancer 152(9) 1847-1862 2023年1月17日  査読有り
    Human papillomavirus (HPV) is causally involved in the development of head and neck squamous cell carcinoma (HNSCC). The integration of HPV drives tumorigenesis through expression of oncogenic viral genes as well as genomic alterations in surrounding regions. To elucidate involvement of epigenetic dysregulation in tumorigenesis, we here performed integrated analyses of the epigenome, transcriptome, and interactome using ChIP-seq, RNA-seq, and Hi-C and 4C-seq for HPV(+) HNSCCs. We analyzed clinical HNSCC using The Cancer Genome Atlas data and found that genes neighboring HPV integration sites were significantly upregulated and were correlated with oncogenic phenotypes in HPV(+) HNSCCs. While we found four HPV integration sites in HPV(+) HNSCC cell line UPCI-SCC-090 through target enrichment sequencing, 4C-seq revealed 0.5-40 Mb of HPV-interacting regions (HPVIRs) where host genomic regions interacted with integrated HPV genomes. While 9% of the HPVIRs were amplified and activated epigenetically forming super-enhancers, the remaining non-amplified regions were found to show a significant increase in H3K27ac levels and an upregulation of genes associated with GO terms e.g. Signaling by WNT and Cell Cycle. Among those genes, ITPR3 was significantly upregulated, involving UPCI-SCC-090-specific super-enhancer formation around the ITPR3 promoter and in the 80-kb-downstream region. The knockdown of ITPR3 by siRNA or CRISPR deletions of the distant enhancer region led to a significant suppression of cell proliferation. The epigenetic activation of HPVIRs was also confirmed in other cell lines, UM-SCC-47 and UM-SCC-104. These data indicate that epigenetic activation in HPVIRs contributes, at least partially, to genesis of HPV(+) HNSCC. This article is protected by copyright. All rights reserved.
  • Tomoya Kurokawa, Syuji Yonekura, Minoru Gotoh, Mitsuhiro Okano, Yuriko Maekawa, Kimihiro Okubo, Yoshitaka Okamoto
    Journal of Allergy and Clinical Immunology: Global 2(2) 100075-100075 2022年12月  査読有り筆頭著者
    BACKGROUND: We previously demonstrated the efficacy of Japanese cedar (JC) pollen sublingual immunotherapy (SLIT) tablets for treating seasonal allergic rhinitis in a clinical trial (trial no. 206-2-1) that covered 5 pollen dispersal seasons from 2015 to 2019. OBJECTIVE: Our aim was to perform post hoc analysis of the 206-2-1 trial data to evaluate the efficacy of JC pollen SLIT tablets for patients with rhinitis induced by pollen from Japanese cypress (JCY), a related Cupressaceae species that has a pollen dispersal season overlapping with that of JC. METHODS: Data were analyzed for 240 patients who received placebo during the first pollen dispersal season in 2015, were then rerandomized to receive JC SLIT tablets (the PA group) or placebo (the PP group) for 18 months (the 2016 and 2017 dispersal seasons), and were observed untreated for 2 years (the 2018 and 2019 dispersal seasons). The PA and PP groups were assigned to "high" and "low" subgroups if their rhinitis symptoms were exacerbated/did not change or decreased, respectively, during the peak JCY pollen dispersal period in 2015. The mean total nasal symptom and medication scores and other outcomes were compared for the high-PP, high-PA, low-PP, and low-PA groups during the 2016 to 2019 peak JCY pollen dispersal periods. RESULTS: The mean total nasal symptom and medication scores were significantly lower for the high-PA and low-PA groups than for the corresponding PP groups over the 4 years of treatment and observation. JCY pollen-specific IgE levels increased in both PA groups. CONCLUSION: JC pollen SLIT tablets effectively suppressed JCY pollinosis symptoms, supporting the clinical relevance of immunologic cross-reactivity between JC and JCY allergens.
  • Satoru Kondo, Atsushi Okabe, Takuya Nakagawa, Keisuke Matsusaka, Masaki Fukuyo, Bahityar Rahmutulla, Hirotomo Dochi, Harue Mizokami, Yuki Kitagawa, Tomoya Kurokawa, Masato Mima, Kazuhira Endo, Hisashi Sugimoto, Naohiro Wakisaka, Kiyoshi Misawa, Tomokazu Yoshizaki, Atsushi Kaneda
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 166598-166598 2022年11月  査読有り

MISC

 34

書籍等出版物

 1
  • 黑川友哉 (担当:分担執筆, 範囲:PMDA)
    科学評論社 2022年11月

講演・口頭発表等

 6

共同研究・競争的資金等の研究課題

 1